Phase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826)

E. Hamilton, J. Meisel, C. Alemany, B. Virginia, N. Lin, R. Wesolowski, G. Mathauda-Sahota, D. Makower, J. Lawrence, D. Faltaos, Z. Mitri, D. Sabanathan, D. Clark, T. Pluard, R. Hui, N. McCarthy, M. Patel

Research output: Contribution to journal › Meeting abstract › peer-review

7 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Phase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826)'. Together they form a unique fingerprint.

Medicine & Life Sciences